Zobrazeno 1 - 10
of 76
pro vyhledávání: ''
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-8 (2021)
BMC Cancer
BMC cancer, Vol. 21, no. 1, p. 1204 (2021)
BMC cancer, Vol. 21, no. 1, p. 1204 [1-8] (2021)
BMC Cancer
BMC cancer, Vol. 21, no. 1, p. 1204 (2021)
BMC cancer, Vol. 21, no. 1, p. 1204 [1-8] (2021)
Background Trastuzumab emtansine (T-DM1) is indicated as second-line treatment for human epidermal growth factor receptor 2 (HER2)-positive metastatic or unresectable locally advanced breast cancer, after progression on trastuzumab and a taxane-based
Autor:
Xiaoyong Huang, Zhiqiang Wu, Wenbo Guo, Zhiyong Liu, Tengfei Li, Xu Bo, Weiguang Yu, Song Chen, Yanqing Wu, Pengfei Wang
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-13 (2021)
BMC Cancer
BMC Cancer
Background Not all patients with unresectable hepatocellular carcinoma (uHCC) benefit from treatment with immune checkpoint inhibitors and molecular-targeted agents. The aim of this retrospective study was to assess the efficacy and safety of pembrol
Publikováno v:
BMC Microbiology, Vol 21, Iss 1, Pp 1-8 (2021)
BMC Microbiology
BMC Microbiology
Background Intra-tumor microbiota have been implicated in pancreatic ductal adenocarcinoma (PDAC) development, treatment response and post-treatment survivorship. Moreover, therapeutic interventions targeting microbiota may improve the response to ch
Autor:
Jerasit Surintrspanont, Suwasin Udomkarnjananun, Yingyos Avihingsanon, Kroonpong Iampenkhae, Thornthun Ueaphongsukkit, Anchalee Avihingsanon, Sivaporn Gatechompol
Publikováno v:
AIDS Research and Therapy, Vol 18, Iss 1, Pp 1-8 (2021)
AIDS Research and Therapy
AIDS Research and Therapy
Background Tenofovir alafenamide (TAF), a novel prodrug of tenofovir (TFV), has become the preferred drug for the treatment of HIV-1 and chronic hepatitis B infection in clinical practice. Results from clinical trials showed that it had better renal
Autor:
Marissa Betts, Ananth Kadambi, Qi Zhao, Isabelle Chabot, Yun Su, Binod Neupane, Kristin Mickle, Rachel Hughes
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-15 (2021)
BMC Cancer
BMC Cancer
Background Eribulin mesylate (ERI; Halaven®) is a microtubule inhibitor approved in the United States for metastatic breast cancer patients with at least two prior chemotherapy regimens for metastatic breast cancer, and in the European Union in loca
Autor:
Antoine Adenis, Stephanie Clisant Delaine, Ludovic Evesque, Julien Fraisse, Brice Pastor, Marc Ychou, Caroline Mollevi, François Ghiringhelli, Thibault Mazard, Patrick Chalbos
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-7 (2021)
BMC Cancer
BMC Cancer, BioMed Central, 2021, 21 (1), pp.564. ⟨10.1186/s12885-021-08312-7⟩
BMC Cancer
BMC Cancer, BioMed Central, 2021, 21 (1), pp.564. ⟨10.1186/s12885-021-08312-7⟩
Background The chemotherapy triplet FOLFOXIRI combined to the anti-VEGF antibody bevacizumab is an option in selected patients with metastatic colorectal cancer. In this setting, RAS-mutated metastatic colorectal cancer do not benefit the same from t
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-8 (2021)
BMC Cancer
BMC Cancer
Background Regorafenib has shown promising results as a second-line therapy for patients with hepatocellular carcinoma (HCC) who progressed on sorafenib. Although there have been several data regarding the efficacy of sequential therapy with sorafeni
Publikováno v:
Journal of Medical Case Reports, Vol 15, Iss 1, Pp 1-6 (2021)
Journal of Medical Case Reports
Journal of Medical Case Reports
Background The outcomes of Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) can improve with allogeneic hematopoietic stem cell transplantation (HSCT) during the first complete remission after treatment with a tyrosine kinase
Autor:
Edward P. Acosta, Jori E. May, Lisle Nabell, Eva Olariu, Andres Forero-Torres, Erica Stringer-Reasor, Dongquan Chen, Eddy S. Yang, Valerie Caterinicchia, Gabrielle B. Rocque, Carla I. Falkson, Christos Vaklavas, Deborah L. Della Manna, Yufeng Li
Publikováno v:
Breast Cancer Research, Vol 23, Iss 1, Pp 1-12 (2021)
Breast Cancer Research : BCR
Breast Cancer Research : BCR
Background Poly (ADP-ribose)-polymerase inhibitors (PARPi) have been approved for cancer patients with germline BRCA1/2 (gBRCA1/2) mutations, and efforts to expand the utility of PARPi beyond BRCA1/2 are ongoing. In preclinical models of triple-negat
Autor:
Huihuang Yin, Lan Chen, Qingxia Huang, Weichun Zhang, Guishan Chen, Xiaoping Yang, Chujia Lin, Fu Chen, Guoshu Yin, Minjie Chen
Publikováno v:
Journal of Ovarian Research, Vol 14, Iss 1, Pp 1-9 (2021)
Journal of Ovarian Research
Journal of Ovarian Research
Background The aims of this study were to compare the efficacy of different androgens measured by liquid chromatography-mass spectrometry (LC-MS/MS) in representing hyperandrogenemia and to evaluate adrenal-origin androgens with a dexamethasone suppr